55,853 Novo Nordisk A/S $NVO Shares Acquired by Salem Investment Counselors Inc.

Salem Investment Counselors Inc. grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 90.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 117,692 shares of the company’s stock after purchasing an additional 55,853 shares during the quarter. Salem Investment Counselors Inc.’s holdings in Novo Nordisk A/S were worth $4,462,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Novo Nordisk A/S by 2,414.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock worth $14,280,000 after buying an additional 286,034 shares during the last quarter. Trust Co. of Vermont acquired a new position in Novo Nordisk A/S in the second quarter valued at $1,250,000. Pine Valley Investments Ltd Liability Co acquired a new position in Novo Nordisk A/S in the second quarter valued at $2,324,000. Myriad Asset Management Advisors LLC bought a new stake in Novo Nordisk A/S during the second quarter valued at $1,846,000. Finally, Tevis Investment Management boosted its position in Novo Nordisk A/S by 65.7% during the first quarter. Tevis Investment Management now owns 74,090 shares of the company’s stock valued at $2,813,000 after acquiring an additional 29,390 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.4%

Novo Nordisk A/S stock opened at $38.03 on Wednesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The firm’s fifty day moving average is $43.13 and its 200 day moving average is $43.90. The company has a market capitalization of $169.83 billion, a PE ratio of 9.60, a PEG ratio of 1.31 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The business had revenue of $11.98 billion during the quarter. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were given a dividend of $0.5786 per share. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date of this dividend was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s payout ratio is currently 20.05%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk is continuing its share-repurchase program of up to DKK 15 billion over 12 months. Buybacks can support earnings per share and provide some demand for the shares, although the program is unlikely to offset broader concerns about growth. Novo Nordisk reports DKK 15 billion buyback program update Novo Nordisk share repurchase programme
• Neutral Sentiment: Analyst commentary highlights a trade-off for investors: Novo Nordisk has strong exposure to the expanding obesity and diabetes-treatment markets, but its valuation, revenue concentration and dependence on the product pipeline remain important risks. The comparison with AbbVie underscores that both companies face material, though different, challenges. AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
• Negative Sentiment: Investors are increasingly questioning whether Novo Nordisk’s pipeline can deliver enough growth to offset slowing visibility in its core franchise. Intensifying competition from Eli Lilly, pricing pressure and concerns about near-term demand are weighing on the shares. Novo Nordisk’s Pipeline Promise Meets a Sobering Reality Check Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $3.29 from $3.43 and its FY2027 forecast to $3.25 from $3.32, both below the roughly $3.53 current consensus estimate. The downward revisions reinforce concerns about earnings momentum. Novo Nordisk analyst earnings estimates
• Negative Sentiment: Recent market coverage attributes the underperformance versus the broader market to the combination of Eli Lilly competition, pricing pressure and limited near-term growth catalysts. Why Novo Nordisk dipped more than the broader market

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of recent analyst reports. Berenberg Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Friday. Finally, Cfra cut Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 target price for the company. in a research note on Tuesday, September 22nd. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $59.44.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.